AMEND news in Tag: multiple endocrine neoplasia
Volunteer for a new research project
Genetic Counselling Student from Cardiff University, Emma Coats, would like to hear from patients with any of the MEN syndromes and who are based in the UK for her research study looking at patient experiences of surveillance (outpatient appointments, test, scans, etc).
NETS in RETS
November 10th each year is NET Cancer Day, initiated by the International Neuroendocrine Cancer Alliance, of which AMEND is a member representing genetic neuroendocrine tumour syndromes. To better explain the link between NETs and RETS (rare endocrine tumours and syndromes), join us for our webinar, NETs in RETS, with Professor Karim Meeran on Thursday 9th November from 18:00-19:00.
AMEND Annual Patient Information Day Success
The sun was shining on Saturday 20th May in London for our Annual Patient Information Day, and our venue beside the Regent’s Canal was the perfect place to receive all the members of our rare endocrine diseases communities who had booked to attend.
AMEND at World MEN 2023
At the end of April, AMEND CEO, Jo Grey, attended the World MEN Scientific Meeting in Marseille, France. She was invited to give a talk about patient perspectives of unmet needs in MEN syndromes.
First Three Speakers for 2023 Event Confirmed!
We are pleased to confirm the first three speakers who will be presenting at our 2023 Annual Patient Information Day on Saturday 6th May in central London. Prof Ashley Grossman, Prof Karim Meeran, and Dr Ruth Casey will be hosting patient Q&A sessions on MEN1, MEN2 and PPGL syndromes respectively.
Impact of COVID-19 on Emotional Health in MEN Syndromes
We present our snapshot report into the impact of the 2020 coronavirus pandemic on our multiple endocrine neoplasia community in which we find a slightly more negative effect in those people who rate their health as 'fair' or 'poor'.